The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study

A randomized, double-blinded, placebo-controlled trial

Brad Spellberg, Ashraf S. Ibrahim, Peter V. Chin-Hong, Dimitrios P. Kontoyiannis, Michele I Morris, John R. Perfect, David Fredricks, Eric P. Brass

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Objectives: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. Methods: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. Results: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22% P=0.1). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). Conclusions: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.

Original languageEnglish
Article numberdkr375
Pages (from-to)715-722
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Volume67
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Mucormycosis
Placebos
Therapeutics
Iron
Chelation Therapy
Safety
liposomal amphotericin B
deferasirox
Neutropenia
Adrenal Cortex Hormones
Cohort Studies
Clinical Trials
Survival
Mortality

Keywords

  • Antifungal
  • Combination therapy
  • Fungal infections
  • Mould infections

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study : A randomized, double-blinded, placebo-controlled trial. / Spellberg, Brad; Ibrahim, Ashraf S.; Chin-Hong, Peter V.; Kontoyiannis, Dimitrios P.; Morris, Michele I; Perfect, John R.; Fredricks, David; Brass, Eric P.

In: Journal of Antimicrobial Chemotherapy, Vol. 67, No. 3, dkr375, 01.03.2012, p. 715-722.

Research output: Contribution to journalArticle

Spellberg, B, Ibrahim, AS, Chin-Hong, PV, Kontoyiannis, DP, Morris, MI, Perfect, JR, Fredricks, D & Brass, EP 2012, 'The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study: A randomized, double-blinded, placebo-controlled trial', Journal of Antimicrobial Chemotherapy, vol. 67, no. 3, dkr375, pp. 715-722. https://doi.org/10.1093/jac/dkr375
Spellberg, Brad ; Ibrahim, Ashraf S. ; Chin-Hong, Peter V. ; Kontoyiannis, Dimitrios P. ; Morris, Michele I ; Perfect, John R. ; Fredricks, David ; Brass, Eric P. / The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study : A randomized, double-blinded, placebo-controlled trial. In: Journal of Antimicrobial Chemotherapy. 2012 ; Vol. 67, No. 3. pp. 715-722.
@article{4edc670316d144c78e71fb77855aed5c,
title = "The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study: A randomized, double-blinded, placebo-controlled trial",
abstract = "Objectives: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. Methods: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. Results: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45{\%} versus 11{\%}, P=0.1) and 90 days (82{\%} versus 22{\%} P=0.1). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18{\%} (2/11) versus 67{\%} (6/9) (P=0.06) and 18{\%} (2/11) versus 56{\%} (5/9) (P=0.2). Conclusions: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.",
keywords = "Antifungal, Combination therapy, Fungal infections, Mould infections",
author = "Brad Spellberg and Ibrahim, {Ashraf S.} and Chin-Hong, {Peter V.} and Kontoyiannis, {Dimitrios P.} and Morris, {Michele I} and Perfect, {John R.} and David Fredricks and Brass, {Eric P.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1093/jac/dkr375",
language = "English",
volume = "67",
pages = "715--722",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study

T2 - A randomized, double-blinded, placebo-controlled trial

AU - Spellberg, Brad

AU - Ibrahim, Ashraf S.

AU - Chin-Hong, Peter V.

AU - Kontoyiannis, Dimitrios P.

AU - Morris, Michele I

AU - Perfect, John R.

AU - Fredricks, David

AU - Brass, Eric P.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Objectives: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. Methods: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. Results: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22% P=0.1). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). Conclusions: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.

AB - Objectives: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. Methods: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. Results: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22% P=0.1). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). Conclusions: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.

KW - Antifungal

KW - Combination therapy

KW - Fungal infections

KW - Mould infections

UR - http://www.scopus.com/inward/record.url?scp=84856967582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856967582&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr375

DO - 10.1093/jac/dkr375

M3 - Article

VL - 67

SP - 715

EP - 722

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

M1 - dkr375

ER -